[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066517A - Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Info

Publication number
ECSP066517A
ECSP066517A EC2006006517A ECSP066517A ECSP066517A EC SP066517 A ECSP066517 A EC SP066517A EC 2006006517 A EC2006006517 A EC 2006006517A EC SP066517 A ECSP066517 A EC SP066517A EC SP066517 A ECSP066517 A EC SP066517A
Authority
EC
Ecuador
Prior art keywords
piridin
triazol
chlorophenyl
trifluorometil
bencil
Prior art date
Application number
EC2006006517A
Other languages
English (en)
Inventor
Susan Marie Reutzel-Edens
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Shella Lenyonga Tameze
Carsten Timpe
Carsten Weber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP066517A publication Critical patent/ECSP066517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1H-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona, composiciones de las mismas, intermediarios de las mismas, métodos de uso de las mismas, procesos para elaborar las mismas, y procesos para elaborar intermediarios de las mismas.
EC2006006517A 2003-10-24 2006-04-21 Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona ECSP066517A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
ECSP066517A true ECSP066517A (es) 2006-10-10

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006517A ECSP066517A (es) 2003-10-24 2006-04-21 Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001311A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ545917A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079600A1 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
AU2016226006B2 (en) 2015-03-04 2021-03-04 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
AU2018331267B2 (en) 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
MX2020005167A (es) 2017-11-17 2020-08-20 Vanda Pharmaceuticals Inc Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.
JP7410137B2 (ja) 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
EP3856338B1 (en) 2018-09-28 2024-11-06 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN115052599A (zh) 2020-02-25 2022-09-13 万达制药公司 以川地匹坦对特应性皮炎的改进治疗
JP2023520369A (ja) 2020-03-26 2023-05-17 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
WO1998015277A2 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
CA2388202A1 (en) * 1999-10-29 2001-05-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
CL2009001310A1 (es) 2009-12-04
CA2542140C (en) 2012-05-29
WO2005042515A1 (en) 2005-05-12
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
CN1863791B (zh) 2011-12-07
PT1675846E (pt) 2010-04-20
KR100848407B1 (ko) 2008-07-28
ATE462700T1 (de) 2010-04-15
TW200524906A (en) 2005-08-01
CA2542140A1 (en) 2005-05-12
US7381826B2 (en) 2008-06-03
MA28329A1 (fr) 2006-12-01
CR8353A (es) 2006-06-06
BRPI0415010A8 (pt) 2018-05-08
IL174926A0 (en) 2006-08-20
DE602004026333D1 (de) 2010-05-12
AR046131A1 (es) 2005-11-23
AU2004285855B2 (en) 2010-12-23
UA82901C2 (en) 2008-05-26
NZ545917A (en) 2009-11-27
MY157375A (en) 2016-06-15
KR20060061388A (ko) 2006-06-07
NO20062371L (no) 2006-05-24
BRPI0415010A (pt) 2006-11-07
US20070078166A1 (en) 2007-04-05
AU2004285855A1 (en) 2005-05-12
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B8 (en) 2011-04-28
NO335090B1 (no) 2014-09-08
BRPI0415010B1 (pt) 2019-07-09
BRPI0415010B8 (pt) 2021-05-25
HRP20100207T1 (hr) 2010-05-31
CN1863791A (zh) 2006-11-15
ZA200603234B (en) 2007-07-25
DK1675846T3 (da) 2010-05-31
EA008881B1 (ru) 2007-08-31
CL2009001311A1 (es) 2009-10-02
PE20050481A1 (es) 2005-09-20
JP4959336B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
ECSP066517A (es) Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
CO4940418A1 (es) Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CR8291A (es) Formas polimorficas 3-(4-amino-1-oxo-1,3 dihidro -isoindol-2-il)-piperidin-2, 6-diona
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20055135L (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
CY1108742T1 (el) Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
MXPA05011962A (es) Oxiarenos substituidos.
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
WO2006124865A3 (en) Biaryls derivatives useful as modulators of ion channels
BRPI0516200A (pt) forma cristalina do cloridrato de (3-ciano-1h-indol-7-il)-[4-(4-fluorfenetril)piperazin-1-i l]metanona
UY28248A1 (es) Compuestos quinicos
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
EE200300365A (et) Parendatud toimega tsüklilise depsipeptiidi kristallivorm
DOP2004001016A (es) Nuevas formas critalinas de {2-[1-(3,5-bistrifluorometibencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-2(-clorofenil) metanona.